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Compared with heart failure (HF) with reduced ejection fraction (HF-REF), the diagnosis of HF with preserved EF 
(HF-PEF) is more challenging. The aim of the study was to assess the prevalence of HF-PEF among patients 
hospitalized for HF, to evaluate the pertinence of HF-PEF diagnosis and to compare HF-PEF and HF-REF patients 
with respect to outcomes. The analysis included 661 Polish patients hospitalized for HF, selected from the European 
Society of Cardiology (ESC)-HF Long-Term Registry. Patients with an EF of ≥50% were included in the HF-PEF 
group and patients with an EF of <50% - in the HF-REF group. The primary end point was all-cause death at 1 year. 
The secondary end point was a composite of all-cause death and rehospitalization for HF at 1 year. HF-PEF was 
present in 187 patients (28%). Of those 187 patients, mitral inflow pattern was echocardiographically assessed in 116 
patients (62%) and classified as restrictive/pseudonormal in 37 patients (20%). Compared with HF-REF subjects, 
patients with HF-PEF were older, more often female, and had a higher prevalence of hypertension, atrial fibrillation 
and sleep apnea. Despite lower B-type natriuretic peptide concentrations and lower prevalence of moderate-to-severe 
mitral regurgitation in patients with HF-PEF, congestive symptoms at admission were as severe as in patients with 
HF-REF. There were no significant differences in in-hospital mortality between the HF groups. One-year mortality 
was high in both groups (17% in HF-PEF vs 21% in HF-REF, p = 0.22). There was a trend toward a lower frequency 
of the secondary end point in the HF-PEF group (32% vs 40%, p = 0.07). In conclusion, in clinical practice, even 
easily obtainable echocardiographic indexes of diastolic dysfunction are relatively rarely acquired. One-year survival 
rate of patients with HF-PEF is not significantly better than that of patients with HF-REF. 
 
 
 
 
 
 
  
The prevalence of heart failure (HF) with preserved ejection fraction (HF-PEF) has increased over the 
last years, with a further increase to be anticipated due to aging of the population and a growing incidence 
of arterial hypertension, obesity, and type 2 diabetes.
1- 3
 In clinical practice, adequate echocardiographic 
evaluation of diastolic function tends to be neglected, as it necessitates a comprehensive examination, 
incorporating all relevant 2-dimensional, pulsed-wave Doppler (PWD) and tissue Doppler imaging (TDI) 
data.
4,5
 Thus, HF-PEF becomes a diagnosis by exclusion, potentially leading to HF misdiagnosis in 
patients in whom the actual cause of dyspnea or diminished exercise capacity fails to be identified. 
Another problem in HF-PEF is the choice of optimal pharmacotherapy, as - so far - no treatment has been 
shown to improve survival in HF-PEF.
3,6,7,8
 The aim of the study was to estimate the prevalence of HF-
PEF in patients hospitalized for HF decompensation, to validate the pertinence of HF-PEF diagnosis in 
these patients, and to assess their clinical profile and outcomes in comparison to patients with HF with 
reduced EF (HF-REF). 
Methods 
The European Society of Cardiology (ESC) HF Long-Term Registry is an on-going, prospective, 
international, observational survey, with 211 cardiology centers from 21 European countries 
participating.
9
 The Registry includes both chronic HF patients presenting to ambulatory care clinics and 
patients admitted to hospital for new-onset or worsening HF. All patients with a diagnosis of HF who are 
aged ≥18 years are eligible for enrollment. The survey was approved by local ethical review boards 
according to the regulations of each participating country. A signed, informed consent was obtained from 
each patient after providing him/her with detailed information on the Registry. 
 
During phase I of the Registry, lasting from May 2011 to April 2013, patients were enrolled on 1 
specific day of the week for 12 consecutive months in each of the participating centers. In phase II/III of 
the Registry (currently on-going), patients are enrolled during 5 consecutive days per trimester. Data on 
clinical characteristics, diagnostic tests performed, and implemented treatment are collected in the 
Registry. Electronic case report forms (eCRFs) enable to describe echocardiographically evaluated left 
ventricular (LV) diastolic function by (1) denominating whether LV filling pattern, assessed by PWD, is 
restrictive/pseudonormal or not (yes vs no); (2) entering the value of the early (E) to late (A) LV filling 
velocity ratio (E/A ratio); and (3) entering the value of wave E deceleration time. Information on the 
presence of LV hypertrophy (LVH) is given dichotomically (yes vs no). It is also possible to enter left 
atrial (LA) dimension (measured in parasternal long-axis view) and LA volume in the Registry's eCRF. 
All patients are followed for 12 months. 
 
The current analysis included Polish patients hospitalized for HF, enrolled during phase I of the 
Registry. To discriminate between patients with HF-PEF and patients with HF-REF, the analysis included 
only those patients who had an echocardiographic examination (with EF assessment) performed during 
index hospitalization. Patients with an EF of ≥50% were included in the HF-PEF group, and patients with 
an EF of <50% were included in the HF-REF group. 
 
To verify the pertinence of HF diagnosis in patients with EF ≥50%, we assessed whether they met the 
echocardiographic criteria for HF-PEF according to the 2012 ESC HF guidelines, that is, the presence of 
LVH and/or LA enlargement (defined as LA dimension of >40 mm and/or LA volume of >34 ml/m
2
) 
and/or LV diastolic dysfunction (defined, for the sake of the current analysis, as restrictive/pseudonormal 
LV filling pattern and/or as E/A ratio of ≥2).6 We also evaluated serum concentrations of B-type 
natriuretic peptide (BNP) and of N-terminal pro-BNP (NT-proBNP) in these patients, and, after 2012 
ESC guidelines, adopted a threshold of ≥100 pg/ml for BNP levels and of ≥300 pg/ml for NT-proBNP as 
justifying HF suspicion in patients hospitalized for exacerbation of symptoms suggestive of HF.
6
 We 
applied ESC guidelines, as the Registry was conducted in the European population. 
  
The HF-PEF and HF-REF groups were compared with regard to clinical profile, initial presentation, 
diagnostic tests results, clinical course and management during index hospitalization, as well as in-
hospital and 1-year outcomes. 
 
The primary end point was all-cause death at 1 year. The secondary end point was a composite of all-
cause death and hospital readmission for HF worsening at 1 year. We assessed the frequency of the 
primary and the secondary end points in both HF groups. In addition, we sought to determine predictors 
of the primary and the secondary end points separately for the HF-PEF and for the HF-REF group. 
 
All statistical analyses were conducted using the SAS software, version 9.2 (SAS Institute Inc., Cary, 
NC). Normally distributed continuous variables were presented as mean (±SD), whereas ordinal variables 
and nonnormally distributed continuous variables were presented as median (interquartile range). The 
HF-PEF and HF-REF groups were compared using the Fisher's exact test for categorical variables and the 
Mann–Whitney test for continuous and ordinal variables. Kaplan–Meier curves were plotted for the 
primary and the secondary end points in both groups. To identify the predictors of the primary and the 
secondary end points, Cox proportional hazards regression analyses were performed. All variables 
predictive of the primary or the secondary end points in univariate analyses were consequently included 
in multivariate models. All tests were 2 tailed. For all tests, a p value of <0.05 was deemed significant. 
Results 
The final analysis included 661 Polish in-hospital patients with echocardiography performed during 
index hospitalization: 187 patients (28%) with EF of ≥50% (HF-PEF group) and 474 patients (72%) with 
EF of <50% (HF-REF group), as shown in Figure 1. In the studied cohort of 661 patients with HF, 229 
subjects (35%) had EF of ≥45%, and 292 patients (44%) had EF of ≥40%. 
 
 
 
Figure 1. Flow chart of patient selection for the current analysis. FU = follow-up; pts = patients. 
 
  
Baseline characteristics, clinical course of index hospitalization, management and diagnostic tests 
performed during hospitalization, as well as in-hospital and 1-year outcomes of patients with HF-PEF and 
HF-REF are presented in Table 1, Table 2, Table 3. 
 
Detailed echocardiographic and laboratory characteristics of patients with HF-PEF are presented in 
Table 2. Of 187 patients in the HF-PEF group, 144 patients (77%) met the echocardiographic criteria for 
HF-PEF, as defined in the Methods section (i.e., the presence of LVH, LA dilation, 
restrictive/pseudonormal LV filling pattern, and/or E/A ratio of ≥2). This was mostly due to the presence 
of LVH (assessed in 183 patients [98%] and confirmed in 96 patients [51% of the whole HF-PEF group]) 
and LA dilation (assessed in 137 patients [73%] and confirmed in 94 patients [50% of the whole HF-PEF 
group]). The PWD mitral inflow velocity pattern was assessed in 116 (62%) of 187 patients in the HF-
PEF group, with exact values of E/A ratio given only in 52 (28%) of 187 patients. Merely 37 patients 
(20% of the whole HF-PEF group) were classified as demonstrating a restrictive/pseudonormal LV filling 
pattern by the Registry's investigators. Deceleration time of the E wave was assessed only in 27 (14%) of 
the 187 patients. 
 
Serum concentrations of NT-proBNP were measured in 62 (33%) of 187 patients with HF-PEF. Of 
those 62 patients, 57 patients (92%) had an NT-proBNP level of ≥300 pg/ml. Serum concentrations of 
BNP were evaluated in 33 (18%) of 187 patients with HF-PEF, all of them had a BNP level of ≥100 
pg/ml. Of 187 patients from the HF-PEF group, 162 patients (87%) either met the prespecified 
echocardiographic criteria for HF-PEF or had an NT-proBNP level of ≥300 pg/ml or a BNP level of ≥100 
pg/ml. 
 
Of 620 patients with data on 1-year follow-up, 122 patients (20%) reached the primary end point: 30 
patients in the HF-PEF group (including 3 patients who died during index hospitalization) and 92 patients 
in the HF-REF group (including 16 patients who died during index hospitalization), as presented in 
Table 3. The secondary end point was reached by 233 patients (38%; Table 3). Kaplan–Meier curves for 
the primary and the secondary end points in both HF groups are plotted in Figures 2 and 3, respectively. 
Univariate analyses of predictors of the primary and the secondary end points in both groups are 
presented in the Supplementary Material (Tables S1 and S2). Multivariate analyses of predictors of the 
primary and the secondary end points for the HF-PEF and the HF-REF group are presented in Table 4. 
Due to the lack of complete data for some of the patients in the Registry, multivariate models included 
only those patients for whom all required parameters were available, that is, 177 patients from the HF-
PEF group and 420 patients from the HF-REF group for the primary end point analyses, and 176 patients 
from the HF-PEF group and 421 patients from the HF-REF group for the secondary end point analyses. 
  
Table 1. Baseline clinical characteristics and previous pharmacotherapy in patients with heart failure with preserved ejection 
fraction (HF-PEF) and in patients with heart failure with reduced ejection fraction (HF-REF) 
Variable HF-PEF (n=187) HF-REF (n=474) P 
    
Age (years) 77 (69-84) 67 (58-76) <0.0001 
Women 111 (59%) 110 (23%) <0.0001 
BMI (kg/m2) 28.0 (25.4-32.4); n=186 27.6 (24.9-30.8); n=472 0.08 
Last known EF before index hospitalization (%) 56 (50-60); n=102 30 (20-38); n=344 <0.0001 
Last known EF (before index hospitalization) ≥50% 83/102 (81%) 14/344 (4%) <0.0001 
Primary described as HF-PEF 20 (11%) 0 (0%) <0.0001 
Primary ischemic etiology of HF 62 (33%) 304 (64%) <0.0001 
Dilated cardiomyopathy 2 (1%) 96 (20%) <0.0001 
Tachycardia-related cardiomyopathy 6 (3%) 14 (3%) 0.81 
Previous HF diagnosis 148/186 (80%) 406/473 (86%) 0.06 
Previous HF hospitalization 78/186 (42%) 265/473 (56%) 0.001 
Hypertension 149 (80%) 325/472 (69%) 0.005 
Coronary artery disease 69 (37%) 293 (62%) <0.0001 
Prior PCI or CABG 31 (17%) 201/472 (43%) <0.0001 
Previously implanted ICD 3 (2%) 87 (18%) <0.0001 
Previously implanted CRT 1 (0.5%) 37 (8%) <0.0001 
Pacemaker 16 (9%) 23 (5%) 0.10 
History of atrial fibrillation 101 (54%) 204 (43%) 0.01 
Prior stroke or TIA 24 (13%) 43 (9%) 0.15 
Peripheral artery disease 32/186 (17%) 70/473 (15%) 0.47 
Diabetes 61 (33%) 170 (36%) 0.47 
Chronic kidney disease 52 (28%) 143 (30%) 0.57 
Sleep apnea 21/185 (11%) 15/466 (3%) <0.0001 
Chronic obstructive pulmonary disease 27 (14%) 70/473 (15%) 1.00 
Current smoker 8 (4%) 77 (16%) <0.0001 
Current or former smoking 69 (37%) 307 (65%) <0.0001 
Loop diuretic 100 (54%) 319 (67%) 0.001 
Thiazide diuretic 21 (11%) 23 (5%) 0.005 
Aldosterone antagonist 57 (31%) 250 (53%) <0.0001 
ACE-I 100 (54%) 317 (67%) 0.002 
ARB 24 (13%) 32 (7%) 0.02 
Nitrates 22 (12%) 54 (11%) 0.89 
β-blocker 133 (71%) 366 (77%) 0.11 
Calcium channel blocker 41 (22%) 55 (12%) 0.001 
Ivabradine 0 (0%) 3 (0.6%) 0.56 
Digoxin 26 (14%) 97 (21%) 0.06 
Amiodarone 11 (6%) 51 (11%) 0.06 
Statin 97 (52%) 271 (57%) 0.23 
Antiplatelets 90 (48%) 271 (57%) 0.04 
Anticoagulants 60 (32%) 156 (33%) 0.86 
Insulin 28 (15%) 67 (14%) 0.81 
    
 
Bold indicates p values of <0.05. 
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; BMI = body mass index; CABG = 
coronary artery bypass grafting; CRT = cardiac resynchronization therapy; EF = ejection fraction; HF = heart failure; ICD = 
implantable cardioverter–defibrillator; PCI = percutaneous coronary intervention; TIA = transient ischemic attack. 
Table 2. Clinical and laboratory status at hospital admission, and echocardiographic findings during index hospitalization in patients 
with heart failure with preserved ejection fraction (HF-PEF) and in patients with heart failure with reduced ejection fraction (HF-
REF) 
 
HF-PEF (n=187) HF-REF (n=474) P 
    
Cardiogenic shock 2 (1%) 14 (3%) 0.26 
NYHA class 3 (3-4) 3 (3-4); n=471  
I 0 (0%) 0 (0%)  
II 41 (22%) 103/471 (22%) 0.93 
III 83 (44%) 212/471 (45%)  
IV 63 (34%) 156/471 (33%)  
Pulmonary rales 126 (67%) 298 (63%) 0.28 
Pulmonary congestion/alveolar oedema on chest X-ray 59/97 (61%) 136/222 (61%) 1.00 
Right ventricular HF 17 (9%) 14 (3%) 0.002 
Peripheral oedema 101 (54%) 239 (50%) 0.44 
Systolic blood pressure (mmHg) 135 (120-160) 120 (110-140) <0.0001 
Diastolic blood pressure (mmHg) 80 (70-90) 75 (70-80); n=473 0.0009 
Heart rate (b.p.m.) 80 (70-100) 80 (70-100) 0.72 
Paced heart rhythm (ECG) 11/186 (6%) 56/469 (12%) 0.02 
AF (ECG) 70/186 (38%) 111/469 (24%) <0.0001 
AF as a cause of admission 64 (34%) 139 (29%) 0.23 
VF or VT as a cause of admission 10 (5%) 55 (12%) 0.01 
ACS as a cause of admission 6 (3%) 71 (15%) <0.0001 
Uncontrolled hypertension as a cause of admission 44 (24%) 38 (8%) <0.0001 
Renal dysfunction as a cause of admission 20 (11%) 62 (13%) 0.44 
NT-proBNP (pg/ml) 1852 (722-5286); n=62 4085 (1691-8675); n=203 0.0001 
BNP (pg/ml) 217 (116-479); n=33 656 (249-1337); n=64 0.0004 
Serum sodium (mmol/l) 140 (137-142); n=185 139 (137-141); n=472 0.005 
Serum creatinine (mg/dl) 1.02 (0.84-1.27); n=185 1.14 (0.91- 1.43); n=472 0.0003 
Hemoglobin (g/dl) 13.3 (11.8-14.3); n=185 13.5 (12.2-14.6); n=469 0.03 
Echocardiography    
Ejection fraction (%) 55 (50-60) 30 (21-38) <0.0001 
LVEDD (mm) 48 (43-52); n=173 60 (54-70); n=444 <0.0001 
Left ventricular hypertrophy 96/183 (53%) 165/446 (37%) 0.0005 
E/A ≥2 2/52 (4%) 42/135 (31%) <0.0001 
E/A <1 33/52 (64%) 64/135 (47%) 0.05 
E/A [1-2) 17/52 (33%) 29/135 (22%) 0.13 
Restrictive/pseudonormal pattern∗ 37/116 (32%) 150/319 (47%) 0.006 
Deceleration time (ms)† 203 (140-290); n=27 149 (108-218); n=64 0.04 
LA dimension (mm) 47 (40-54); n=94 48 (43-52); n=229 0.71 
LA dimension >40 mm 70/94 (75%) 193/229 (84%) 0.71 
LA volume (ml) 73 (45-110); n=43 55 (45-90); n=66 0.36 
LA volume >34 ml/m2 24/43 (56%) 26/65 (40%) 0.12 
Aortic stenosis‡ 25/185 (14%) 31/466 (7%) 0.008 
Aortic regurgitation‡ 13/186 (7%) 43/465 (9%) 0.44 
Mitral regurgitation‡ 79/185 (43%) 272/466 (58%) <0.0001 
Tricuspid regurgitation‡ 72/186 (39%) 199/466 (43%) 0.38 
    
 
Bold indicates p values of <0.05. 
ACS = acute coronary syndrome; AF = atrial fibrillation; BNP = B-type natriuretic peptide; E/A = early to late left ventricular 
filling velocity ratio; ECG = electrocardiogram; LA = left atrium; LVEDD = left ventricular end-diastolic diameter; NTproBNP = 
N-terminal proBNP; NYHA = New York Heart Association; VF = ventricular fibrillation; VT = ventricular tachycardia. 
∗ Of mitral inflow. 
† Of the E wave. 
‡ Moderate or severe. 
Table 3. Management during index hospitalization, clinical status, laboratory findings and pharmacotherapy at discharge, as well as 
in-hospital and long-term outcomes of patients with heart failure with preserved ejection fraction (HF-PEF) and of patients with 
heart failure with reduced ejection fraction (HF-REF) 
Variable HF-PEF (n=187) HF-REF (n=474) P 
    
Inotropic support 9 (5%) 82/472 (17%) <0.0001 
Intravenous nitrates 25 (13%) 56/471 (12%) 0.60 
Intravenous diuretics 106 (57%) 289/472 (61%) 0.29 
Coronary angiography 24 (13%) 160/471 (34%) <0.0001 
PCI/CABG 10 (5%) 75/472 (16%) <0.0001 
Holter-ECG 67 (36%) 164/470 (35%) 0.86 
Exercise test 18/176 (10%) 63/463 (14%) 0.29 
Heart rate (b.p.m.) ∗ 70 (65-80) 70 (65-80) 0.89 
Systolic blood pressure (mmHg)∗ 120 (110-130) 115 (105-125) <0.0001 
NYHA class∗ 2 (2-3) 2 (2-3) 0.002 
I 11 (6%) 16 (4%) 
II 126 (69%) 268 (59%) 
III 45 (25%) 165 (36%) 
IV 2 (1%) 9 (2%) 
Serum creatinine (mg/dl)∗ 1.05 (0.88-1.31); n=137 1.12 (0.94-1.41); n=354 0.04 
Loop diuretic∗ 134 (73%) 390 (85%) 0.0004 
Thiazide diuretic∗ 16 (9%) 18 (4%) 0.02 
Aldosterone antagonist∗ 92 (50%) 345 (75%) <0.0001 
ACE-I∗ 114 (62%) 377 (82%) <0.0001 
ARB∗ 30 (16%) 33 (7%) 0.001 
Nitrates∗ 16 (9%) 49 (11%) 0.56 
β-blocker∗ 151 (82%) 428 (94%) <0.0001 
Bisoprolol∗ 58 (32%) 143 (31%) 1.00 
Carvedilol∗ 29 (16%) 193 (42%) <0.0001 
Metoprolol∗ 41 (22%) 55 (12%) 0.001 
Nebivolol∗ 14 (8%) 34 (7%) 1.00 
Target β-blocker dose reached† 10 (5%) 38 (8%) 0.25 
Calcium channel blocker∗ 51 (28%) 51 (11%) <0.0001 
Ivabradine∗ 0 (0%) 6 (1%) 0.19 
Digoxin∗ 33 (18%) 119 (26%) 0.03 
Amiodarone∗ 11 (6%) 69 (15%) 0.001 
Statin∗ 111 (60%) 332 (73%) 0.003 
Antiplatelets∗ 91 (50%) 304 (66%) 0.0001 
Anticoagulants∗ 90 (49%) 202 (44%) 0.29 
Insulin∗ 29 (16%) 76 (17%) 0.91 
Hospitalization length (days) 7 (4-10) 7 (4-12) 0.26 
Death during hospitalization 3 (1.6%) 16 (3.4%) 0.30 
Death at 1 year 30/182 (17%) 92/438 (21%) 0.22 
Death or rehospitalization at 1 year 58/182 (32%) 175/438 (40%) 0.07 
    
 
Bold indicates p values of <0.05. 
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CABG = coronary artery bypass grafting; 
ECG = electrocardiogram; NYHA = New York Heart Association; PCI = percutaneous coronary intervention. 
∗ At discharge (in patients who survived to hospital discharge, i.e., in 184 patients with HF-PEF, and in 458 patients with HF-
REFs). 
† That is: bisoprolol ≥10 mg daily, carvedilol ≥50 mg daily, metoprolol ≥200 mg daily, or nebivolol ≥10 mg daily. 
  
 
 
 
Figure 2. Kaplan–Meier curves for the primary end point in patients with HF-PEF and in patients with HF-REF. 
 
 
 
Figure 3. Kaplan–Meier curves for the secondary end point in patients with HF-PEF and in patients with HF-REF. 
  
Table 4. Multivariate analyses of predictors of the primary and the secondary end points in patients with heart failure with preserved 
ejection fraction and in patients with heart failure with reduced ejection fraction 
 
Primary endpoint  Secondary endpoint 
HR (95% CI) P  HR (95% CI) P 
 
Heart failure with preserved ejection fraction 
 Age (per 10 years) 2.04 (1.09-3.81) 0.03  1.37 (0.91-2.04) 0.13 
 History of atrial fibrillation - -  2.22 (0.87-5.65) 0.096 
 NYHA class∗ (per 1 class) 2.91 (1.31-6.47) 0.009  2.35 (1.32-4.18) 0.004 
 Heart rate∗ (per 10 b.p.m.) - -  0.96 (0.83-1.13) 0.65 
 Aortic stenosis† 3.73 (1.10-12.62) 0.04  3.44 (1.18-9.98) 0.02 
 Tricuspid regurgitation† 2.49 (0.91-6.78) 0.07  1.13 (0.46-2.75) 0.80 
 Serum sodium∗ (per 1 mmol/l) - -  0.91 (0.84-0.999) 0.047 
 Serum creatinine∗ (per 1 mg/dl) 1.68 (0.74-3.82) 0.22  2.02 (0.88-4.63) 0.096 
 Hemoglobin∗ (per 1 g/dl) 0.84 (0.66-1.08) 0.17  0.93 (0.75-1.15) 0.49 
Heart failure with reduced ejection fraction 
 Age (per 10 years) 1.45 (1.15-1.83) 0.002  - - 
 Women - -  1.95 (1.17-3.25) 0.01 
 Peripheral artery disease 1.69 (0.85-3.33) 0.13  2.22 (1.19-4.15) 0.01 
 Chronic obstructive pulmonary disease - -  1.37 (0.76-2.47) 0.30 
 NYHA class∗ (per 1 class) 1.89 (1.26-2.85) 0.002  1.60 (1.15-2.22) 0.005 
 Systolic blood pressure∗ (per 10 mmHg) 0.96 (0.87-1.07) 0.47  0.98 (0.89-1.07) 0.65 
 Heart rate∗ (per 10 b.p.m.) - -  1.06 (0.98-1.15) 0.17 
 Ejection fraction (per 5%) 0.85 (0.73-0.99) 0.04  0.87 (0.77-0.98) 0.02 
 Aortic regurgitation† 1.90 (0.87-4.12) 0.11  1.72 (0.82-3.60) 0.15 
 Mitral regurgitation† 1.19 (0.67-2.11) 0.56  1.18 (0.73-1.88) 0.50 
 Tricuspid regurgitation† 0.92 (0.52-1.63) 0.78  1.02 (0.63-1.64) 0.94 
 Serum sodium∗ (per 1 mmol/l) 0.92 (0.86-0.97) 0.004  0.99 (0.94-1.04) 0.64 
 Serum creatinine∗ (per 1 mg/dl) 1.11 (0.80-1.54) 0.54  - - 
 Hemoglobin∗ (per 1 g/dl) 0.94 (0.82-1.08) 0.39  - - 
 PCI/CABG during hospitalization - -  0.61 (0.30-1.23) 0.17 
 ACE-I or ARB‡ - -  0.40 (0.21-0.76) 0.006 
      
 
Bold indicates p values of <0.05. 
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CABG = coronary artery bypass grafting; 
CI = confidence interval; HR = hazard ratio; NYHA = New York Heart Association; PCI = percutaneous coronary intervention. 
∗ At hospital admission. 
† Moderate or severe. 
‡ At hospital discharge. 
 
 
 
 
 
  
Discussion 
In the presented analysis, the prevalence of HF-PEF among hospitalized HF patients was 28%, 35%, 
and 44%, depending on the cut-off value for “preserved” EF (≥50%, ≥45%, and ≥40%, respectively). 
This is similar to HF-PEF prevalence observed in the whole population of hospitalized ESC-HF Long-
Term Registry patients (31% for “preserved” EF threshold of >45%).9 Data from previously published 
studies demonstrate that the proportion of patients with HF-PEF among all patients with HF varies widely 
from 25% to 71%, depending on the adopted threshold for “preserved” EF, as well as on the clinical 
setting and study type.
1,2,3,10,11,12
 In previous large, prospective registries, patients with preserved EF 
constituted approximately half of patients hospitalized for acute HF.
13,14,15
 
 
The echocardiographic criteria for HF-PEF we adopted in the current analysis were fairly mild, that is, 
required the presence of only one of the abnormalities suggestive of LV diastolic dysfunction, including 
the presence of LA dilation, which is very unspecific for LV diastolic dysfunction and might be 
attributable to a number of other conditions, such as hypertension or atrial fibrillation (both highly 
prevalent in the population studied).
4,5,16,17
 Still, almost one quarter of the HF-PEF group in our study did 
not fulfill those mild echocardiographic criteria. Furthermore, the diagnosis of HF-PEF was actually 
confirmed by the presence of restrictive/pseudonormal mitral inflow pattern in merely 20% of patients. 
Thus, the remaining 80% of patients with EF ≥50% and no convincing evidence for significant LV 
diastolic dysfunction might have been misdiagnosed with HF. Possibly, some of those patients were 
classified as HF-PEF based on the E/A ratio of <1, which may be indicative of impaired LV relaxation.
4
,
5
 
However, it has been well established that in healthy persons aged >60 years, the E/A ratio decreases 
below 1 (together with a prolongation of the E wave deceleration time).
4,5,18
 Therefore, the diagnosis of 
HF-PEF based solely on the value of E/A ratio <1 in patients more than 60 years old is not justified 
(median age in the studied HF-PEF group was 77 years). According to the present guidelines, evaluation 
of LV diastolic function in patients with suspected HF-PEF should be largely based on the estimation of 
TDI-assessed early diastolic velocities of mitral annulus (e') and the E/e' ratio.
4,5,6
 Unfortunately, the 
eCRF of the ESC-HF Long-Term Registry did not allow entering TDI-derived measurements. 
 
The clinical profile of patients with preserved EF in our analysis corresponds to the previously 
described characteristics of HF-PEF population, with a higher prevalence of hypertension, atrial 
fibrillation, obesity, and female gender, and patients being older compared with HF-REF 
population.
2,3,10,11,12,13,14,15,19,20
 Interestingly, although coronary artery disease (CAD) is a risk factor for 
the development of diastolic dysfunction, this ultimately progresses to systolic dysfunction in a vast 
number of patients with CAD; thus, the observed prevalence of CAD is higher in patients with HF-REF 
than in patients with HF-PEF.
2,12,13,14,21,22
 Of note, many patients with HF-PEF may in fact exhibit 
impaired longitudinal and circumferential systolic LV function, despite preserved global EF.
20,23
 
Importantly, HF-PEF is typically accompanied by a number of noncardiac co-morbidities (including 
diabetes, sleep apnea, chronic obstructive pulmonary disease, chronic kidney disease, and anemia), which 
- on one hand - might be involved in its development, and - on the other hand - deteriorate prognosis in 
HF.
2,10,12,21,24,25
 
 
Despite preserved EF, lower prevalence of moderate-to-severe mitral regurgitation and lower 
BNP/NT-proBNP concentrations on hospital admission, the severity of congestive symptoms in patients 
presenting with HF-PEF was similar to that observed in HF-REF. Consequently, the proportion of 
patients receiving intravenous nitrate or diuretic treatment was comparable in both HF groups. 
Nevertheless, patients with HF-REF more often required inotropic support. 
 
In-hospital mortality rate of patients with HF-PEF was twice as low as of patients with HF-REF, but 
due to the low number of events, the difference did not reach statistical significance. Among patients who 
survived to hospital discharge, subjects with HF-PEF were characterized by a better functional status at 
discharge than those with HF-REF. However, no evident benefit in terms of 1-year mortality was 
demonstrated for the HF-PEF group. Previous studies have brought inconsistent results on survival in 
patients with HF-PEF compared with HF-REF, with similar prognosis in both HF groups demonstrated 
predominantly in epidemiological studies and registries, and with a 32% lower risk of death in HF-PEF in 
a meta-analysis including randomized clinical trials.
2,3,10,11,12,13,14,15,21,26,27
 According to previously 
published analyses, the most important risk factors for reduced survival in HF-PEF include advanced age, 
male gender, CAD, a greater noncardiac co-morbidity burden, renal impairment, hyponatremia, and both 
very high (≥35 kg/m2) and normal-to-low (<23.5 kg/m2) body mass index.14,26,28,29,30 To date, none of the 
medications routinely used in HF-REF has shown efficacy in improving prognosis of patients with HF-
PEF.
3,6,7,8
 
 
The limitations of our study arise largely from the type of data (i.e., registry derived) we analyzed. 
First, there was a certain proportion of data missing for some of the patients. Second, the eCRF enabled 
investigators to enter only data predefined by the coordinators of the registry. In terms of evaluation of 
diastolic function, those were limited to PWD-assessed parameters of mitral inflow. Regretfully, no data 
on other important indexes of diastolic function were gathered in the registry. Therefore, definitive 
verification of the pertinence of HF-PEF diagnosis was not possible. Moreover, we were not able to 
assess how often each of those parameters is actually implemented in everyday clinical practice. 
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